La Jolla Pharmaceutical Company
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From La Jolla Pharmaceutical Company
Mead Johnson pulls challenged claims before National Advertising Division began a review in its SWIFT process, but not before Nestlé Nutrition, which markets Gerber infant formula, submitted its challenge.
Public Company Edition: The pace of US initial public offerings slowed a bit in April and May but could ramp back up in June as biopharma investor sentiment rebounds. Also, drug developers continue to go public via SPAC mergers, most recently Valo Health with a $2.8bn post-deal valuation.
Coronavirus Notebook: Heterologous Vaccine Study Shows Positive Results, UK Offers Earlier Second Dose To Vulnerable People
The European Medicines Agency has extended the time that Comirnaty can spend in a fridge after defrosting and could this week issue advice to member states on sotrovimab for use in COVID-19 patients. Norway’s BerGenBio has published top-line data from a Phase II trial of of bemcentinib, and IcanoMAB has outlined the potential of its anti-IL-1R7 antibody.
Viewers spend more time on print ads that have more lengthy important safety information or a brief summary but impact on understanding is unclear, OPDP study finds. Another study finds exaggerated images of drug benefits in TV ads unsurprisingly can mislead consumers.
- Other Names / Subsidiaries
- La Jolla Pharma, LLC
- Tetraphase Pharmaceuticals, Inc.